MX2021014193A - Moleculas de enlace biespecificas anti-ror1/anti-cd3. - Google Patents
Moleculas de enlace biespecificas anti-ror1/anti-cd3.Info
- Publication number
- MX2021014193A MX2021014193A MX2021014193A MX2021014193A MX2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A MX 2021014193 A MX2021014193 A MX 2021014193A
- Authority
- MX
- Mexico
- Prior art keywords
- ror1
- binding molecules
- bispecific binding
- bispecific
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852039P | 2019-05-23 | 2019-05-23 | |
| PCT/US2020/034281 WO2020237173A1 (en) | 2019-05-23 | 2020-05-22 | Anti-ror1/anti-cd3 bispecific binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014193A true MX2021014193A (es) | 2022-01-06 |
Family
ID=71078637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014193A MX2021014193A (es) | 2019-05-23 | 2020-05-22 | Moleculas de enlace biespecificas anti-ror1/anti-cd3. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227866A1 (https=) |
| EP (1) | EP3972999A1 (https=) |
| JP (1) | JP7611171B2 (https=) |
| KR (1) | KR20220012313A (https=) |
| CN (1) | CN113874399B (https=) |
| AU (1) | AU2020277489A1 (https=) |
| BR (1) | BR112021023026A2 (https=) |
| CA (1) | CA3139111A1 (https=) |
| MX (1) | MX2021014193A (https=) |
| TW (1) | TWI899079B (https=) |
| WO (1) | WO2020237173A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023504620A (ja) * | 2019-12-06 | 2023-02-06 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物 |
| CA3166286A1 (en) | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
| MX2023009022A (es) * | 2021-02-02 | 2023-10-23 | Numab Therapeutics AG | Anticuerpos multiespecificos con especificidad para ror1 y cd3. |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023000791A1 (en) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| WO2023056556A1 (en) * | 2021-10-07 | 2023-04-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2981281B1 (en) | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN110627907B (zh) * | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3091032A1 (en) | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| WO2017125897A1 (en) * | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| KR20180100238A (ko) * | 2016-01-22 | 2018-09-07 | 얀센 바이오테크 인코포레이티드 | 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3166286A1 (en) * | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
-
2020
- 2020-05-22 CN CN202080038180.6A patent/CN113874399B/zh active Active
- 2020-05-22 EP EP20732061.5A patent/EP3972999A1/en active Pending
- 2020-05-22 WO PCT/US2020/034281 patent/WO2020237173A1/en not_active Ceased
- 2020-05-22 US US17/613,251 patent/US20220227866A1/en active Pending
- 2020-05-22 JP JP2021569109A patent/JP7611171B2/ja active Active
- 2020-05-22 MX MX2021014193A patent/MX2021014193A/es unknown
- 2020-05-22 KR KR1020217041982A patent/KR20220012313A/ko not_active Withdrawn
- 2020-05-22 CA CA3139111A patent/CA3139111A1/en active Pending
- 2020-05-22 BR BR112021023026A patent/BR112021023026A2/pt unknown
- 2020-05-22 TW TW109117258A patent/TWI899079B/zh active
- 2020-05-22 AU AU2020277489A patent/AU2020277489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220012313A (ko) | 2022-02-03 |
| US20220227866A1 (en) | 2022-07-21 |
| EP3972999A1 (en) | 2022-03-30 |
| AU2020277489A1 (en) | 2021-11-25 |
| BR112021023026A2 (pt) | 2022-01-04 |
| JP7611171B2 (ja) | 2025-01-09 |
| CN113874399A (zh) | 2021-12-31 |
| CA3139111A1 (en) | 2020-11-26 |
| TW202110887A (zh) | 2021-03-16 |
| CN113874399B (zh) | 2025-07-11 |
| WO2020237173A1 (en) | 2020-11-26 |
| TWI899079B (zh) | 2025-10-01 |
| JP2022533418A (ja) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014193A (es) | Moleculas de enlace biespecificas anti-ror1/anti-cd3. | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| PH12021551487A1 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| WO2021022304A3 (en) | Bispecific anti lrrc15 and cd3epsilon antibodies | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| CR20210622A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| EA201790060A1 (ru) | Биспецифические cd33- и cd3-связывающие белки | |
| MX2024009277A (es) | Anticuerpos anti proteina de muerte programada 1 (pd-1) y usos de estos. | |
| ZA202100723B (en) | Fc binding fragments comprising a cd137 antigen-binding site | |
| PH12019500668B1 (en) | Anti-lag-3 antibodies and compositions | |
| MY207784A (en) | Anti-cd73 antibodies | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| PH12021552538A1 (en) | Heavy chain antibodies binding to psma | |
| MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
| EA201890368A1 (ru) | Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение | |
| MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| MY176475A (en) | Human antibodies to pd-1 | |
| MX2017015380A (es) | Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33. | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| MX2024005841A (es) | Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias. | |
| MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. |